Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated levels of C-reactive protein (CRP) are associated with increased risks of ischemic heart disease and ischemic cerebrovascular disease. We tested whether this is a causal association. METHODS: We studied 10,276 persons from a general population cohort, including 1786 in whom ischemic heart disease developed and 741 in whom ischemic cerebrovascular disease developed. We examined another 31,992 persons from a cross-sectional general population study, of whom 2521 had ischemic heart disease and 1483 had ischemic cerebrovascular disease. Finally, we compared 2238 patients with ischemic heart disease with 4474 control subjects and 612 patients with ischemic cerebrovascular disease with 1224 control subjects. We measured levels of high-sensitivity CRP and conducted genotyping for four CRP polymorphisms and two apolipoprotein E polymorphisms. RESULTS: The risk of ischemic heart disease and ischemic cerebrovascular disease was increased by a factor of 1.6 and 1.3, respectively, in persons who had CRP levels above 3 mg per liter, as compared with persons who had CRP levels below 1 mg per liter. Genotype combinations of the four CRP polymorphisms were associated with an increase in CRP levels of up to 64%, resulting in a theoretically predicted increased risk of up to 32% for ischemic heart disease and up to 25% for ischemic cerebrovascular disease. However, these genotype combinations were not associated with an increased risk of ischemic vascular disease. In contrast, apolipoprotein E genotypes were associated with both elevated cholesterol levels and an increased risk of ischemic heart disease. CONCLUSIONS: Polymorphisms in the CRP gene are associated with marked increases in CRP levels and thus with a theoretically predicted increase in the risk of ischemic vascular disease. However, these polymorphisms are not in themselves associated with an increased risk of ischemic vascular disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional biomarkers, including apo B, lipoprotein(a), high-sensitivity C-reactive protein (CRP), coronary artery calcification score, and ankle-brachial index, are independent risk factors associated with increased risk of ASCVD events and may be helpful when the lipid management goal is unclear.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [284]
In the citing paper
“The value of hsCRP as a CV risk factor appears similar to that of conventional CV risk factors – hsCRP is not a causal factor for CV disease and serves as a biomarker only [36].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [36]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“Yet, despite the high CV morbidity and mortality risk, PAD patients are usually inadequately managed compared with CAD patients [511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationFasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Mendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Avoiding bias from weak instruments in Mendelian randomization studies
Burgess, S., Thompson, S. G., & CRP CHD Genetics Collaboration (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr036 · Cited by 3,952
Mendelian Randomization as an Approach to Assess Causality Using Observational Data
Sekula, P., Del Greco M, F., Pattaro, C., & Köttgen, A. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010098 · Cited by 2,351
Chiu, J.-J., & Chien, S. (2011) · Physiological Reviews · doi:10.1152/physrev.00047.2009 · Cited by 2,280
Stroke risk factors, genetics, and prevention
Boehme, A. K., Esenwa, C., & Elkind, M. S. V. (2017) · Circulation Research · doi:10.1161/circresaha.116.308398 · Cited by 1,952
Recent Developments in Mendelian Randomization Studies
Zheng, J., Baird, D., Borges, M.-C., Bowden, J., Hemani, G., Haycock, P., Evans, D. M., & Smith, G. D. (2017) · Current Epidemiology Reports · doi:10.1007/s40471-017-0128-6 · Cited by 1,147
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
“Therefore, the CANTOS trial opens new paths to personalized therapeutic approaches for secondary prevention of CVDs.”
BackgroundInfluentialAnderson, T. J., Grégoire, J., Hegele, R. A., Couture, P., Mancini, G. B. J., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C., Grover, S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.11.032 · Cited by 770
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Varbo, A., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Circulation · doi:10.1161/circulationaha.113.003008 · Cited by 692
Self-citationAcute-phase proteins: As diagnostic tool
Jain, S., Gautam, V., & Naseem, S. (2011) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.76489 · Cited by 652
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Structure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 638
“sufficiently powered studies are available, can be used to exclude causality as this was recently done for C-reactive protein (CRP) and CHD (214;215).”
BackgroundC Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC) (2011) · BMJ · doi:10.1136/bmj.d548 · Cited by 642
Benn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1563 · Cited by 632
Self-citationJBS3 Board (2014) · Heart · doi:10.1136/heartjnl-2014-305693 · Cited by 608
Haycock, P. C., Burgess, S., Wade, K. H., Bowden, J., Relton, C., & Davey Smith, G. (2016) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.118216 · Cited by 600
An Integrated View of Humoral Innate Immunity: Pentraxins as a Paradigm
Bottazzi, B., Doni, A., Garlanda, C., & Mantovani, A. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101305 · Cited by 592
Relton, C. L., & Davey Smith, G. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr233 · Cited by 567
Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer
Allin, K. H., & Nordestgaard, B. G. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.599831 · Cited by 553
Self-citationStudy, A. C., Bojesen, S. E., Study, A. O. C., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), (GENICA), G. E. I. A. B. C., (SWE-BRCA), S. B. C. S., The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), (EMBRACE), E. S. O. B. &. B. M. C., (GEMO), G. M. O. C. R. I. B. M. C., Pooley, K. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2566 · Cited by 528
Genetics of Human Cardiovascular Disease
Kathiresan, S., & Srivastava, D. (2012) · Cell · doi:10.1016/j.cell.2012.03.001 · Cited by 496
“…of C-reactive protein gene (CRP) variants that affect plasma CRP concentrations, performed in thousands of individuals, did not show an association between these variants and ischemic vascular disease or coronary artery disease (Elliott et al., 2009; Wensley et al., 2011; Zacho et al., 2008).”
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
High-Sensitivity C-Reactive Protein and Cardiovascular Disease
Yousuf, O., Mohanty, B. D., Martin, S. S., Joshi, P. H., Blaha, M. J., Nasir, K., Blumenthal, R. S., & Budoff, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.016 · Cited by 494
Inflammation and type 2 diabetes
Calle, M. C., & Fernandez, M. L. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.006 · Cited by 488
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.185 · Cited by 477
Helleberg, M., Afzal, S., Kronborg, G., Larsen, C. S., Pedersen, G., Pedersen, C., Gerstoft, J., Nordestgaard, B. G., & Obel, N. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis933 · Cited by 463
“The Copenhagen General Population Study is a prospective study of a cohort of individuals randomly selected from greater Copenhagen [9–11].”
BackgroundSelf-citationVitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study
Mokry, L. E., Ross, S., Ahmad, O. S., Forgetta, V., Smith, G. D., Leong, A., Greenwood, C. M. T., Thanassoulis, G., & Richards, J. B. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001866 · Cited by 445
Ridker, P. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.037 · Cited by 414
Benn, M., Watts, G. F., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw028 · Cited by 400
Self-citationInflammatory Biomarkers and Exacerbations in Chronic Obstructive Pulmonary Disease
Thomsen, M., Ingebrigtsen, T. S., Marott, J. L., Dahl, M., Lange, P., Vestbo, J., & Nordestgaard, B. G. (2013) · JAMA · doi:10.1001/jama.2013.5732 · Cited by 401
Self-citationInnate sensing of oxidation-specific epitopes in health and disease
Binder, C. J., Papac-Milicevic, N., & Witztum, J. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.63 · Cited by 403
Genetics of Coronary Artery Disease
McPherson, R., & Tybjaerg-Hansen, A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306566 · Cited by 371
Self-citationErratum: Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.33 · Cited by 363
Inflammation in End-Stage Renal Disease-What Have We Learned in 10 Years?
Carrero, J. J., & Stenvinkel, P. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00784.x · Cited by 354
Bohula, E. A., Giugliano, R. P., Cannon, C. P., Zhou, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Blazing, M. A., & Braunwald, E. (2015) · Circulation · doi:10.1161/circulationaha.115.018381 · Cited by 340
Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
Trpkovic, A., Resanovic, I., Stanimirovic, J., Radak, D., Mousa, S. A., Cenic-Milosevic, D., Jevremovic, D., & Isenovic, E. R. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.992063 · Cited by 321
Koenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315
Anti-inflammatory therapeutics for the treatment of atherosclerosis
Charo, I. F., & Taub, R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3444 · Cited by 306
Mendelian randomization: where are we now and where are we going?
Burgess, S., Timpson, N. J., Ebrahim, S., & Davey Smith, G. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv108 · Cited by 304
Timpson, N. J., Nordestgaard, B. G., Harbord, R. M., Zacho, J., Frayling, T. M., Tybjærg-Hansen, A., & Davey Smith, G. (2011) · International Journal of Obesity · doi:10.1038/ijo.2010.137 · Cited by 310
Self-citationHeld, C., White, H. D., Stewart, R. A. H., Budaj, A., Cannon, C. P., Hochman, J. S., Koenig, W., Siegbahn, A., Steg, P. G., Soffer, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005077 · Cited by 291
Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction
Wang, T. J. (2011) · Circulation · doi:10.1161/circulationaha.109.912568 · Cited by 294
Curcio, C. A., Johnson, M., Huang, J.-D., & Rudolf, M. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.08.001 · Cited by 286
Nordestgaard, B. G., Palmer, T. M., Benn, M., Zacho, J., Tybjærg-Hansen, A., Davey Smith, G., & Timpson, N. J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001212 · Cited by 280
Self-citationInflammatory risk factors, biomarkers and associated therapy in ischaemic stroke
Esenwa, C. C., & Elkind, M. S. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.125 · Cited by 281
Afzal, S., Brondum-Jacobsen, P., Bojesen, S. E., & Nordestgaard, B. G. (2014) · BMJ · doi:10.1136/bmj.g6330 · Cited by 270
Self-citationEvaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Relton, C. L., & Davey Smith, G. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000356 · Cited by 254
Pentraxins: Structure, Function, and Role in Inflammation
Du Clos, T. W. (2013) · ISRN Inflammation · doi:10.1155/2013/379040 · Cited by 248
The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease
Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., & Iskandrian, A. E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.047 · Cited by 247
Coronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 236
Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease
Thomsen, M., Dahl, M., Lange, P., Vestbo, J., & Nordestgaard, B. G. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1113oc · Cited by 245
Self-citationOxidative Stress, Inflammation, and Neuroprogression in Chronic PTSD
Miller, M. W., Lin, A. P., Wolf, E. J., & Miller, D. R. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000167 · Cited by 237
Lipid parameters for measuring risk of cardiovascular disease
Arsenault, B. J., Boekholdt, S. M., & Kastelein, J. J. P. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.223 · Cited by 225
“The associations between genetic variants of CRP , plasma levels of this protein, and CVD risk have been investigated in a number of Mendelian randomization studies”
BackgroundSerum C-reactive protein is linked to cerebral microstructural integrity and cognitive function
Wersching, H., Duning, T., Lohmann, H., Mohammadi, S., Stehling, C., Fobker, M., Conty, M., Minnerup, J., Ringelstein, E. B., Berger, K., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d7b45b · Cited by 235
Short Telomere Length, Cancer Survival, and Cancer Risk in 47102 Individuals
Weischer, M., Nordestgaard, B. G., Cawthon, R. M., Freiberg, J. J., Tybjærg-Hansen, A., & Bojesen, S. E. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt016 · Cited by 228
Self-citationC-reactive protein is a mediator of cardiovascular disease
Bisoendial, R. J., Boekholdt, S. M., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq238 · Cited by 232
C-Reactive Protein and Risk of Lung Cancer
Chaturvedi, A. K., Caporaso, N. E., Katki, H. A., Wong, H.-L., Chatterjee, N., Pine, S. R., Chanock, S. J., Goedert, J. J., & Engels, E. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0454 · Cited by 217
Thomsen, M., & Nordestgaard, B. G. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.10522 · Cited by 215
Self-citationChronic Inflammatory Diseases and Cardiovascular Risk: A Systematic Review
Roifman, I., Beck, P. L., Anderson, T. J., Eisenberg, M. J., & Genest, J. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.040 · Cited by 214
Nørgaard, M., Ehrenstein, V., & Vandenbroucke, J. P. (2017) · Clinical Epidemiology · doi:10.2147/clep.s129879 · Cited by 210
Mendelian randomization studies in coronary artery disease
Jansen, H., Samani, N. J., & Schunkert, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu208 · Cited by 212
Association of C-Reactive Protein With Cognitive Impairment
Noble, J. M., Manly, J. J., Schupf, N., Tang, M. X., Mayeux, R., & Luchsinger, J. A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.308 · Cited by 203
Mendelian Randomization: Nature's Randomized Trial in the Post–Genome Era
Thanassoulis, G., & O’Donnell, C. J. (2009) · JAMA · doi:10.1001/jama.2009.812 · Cited by 209
Carrero, J. J., & Stenvinkel, P. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02720409 · Cited by 199
Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206
Novel methodologies for biomarker discovery in atherosclerosis
Hoefer, I. E., Steffens, S., Ala-Korpela, M., Bäck, M., Badimon, L., Bochaton-Piallat, M.-L., Boulanger, C. M., Caligiuri, G., Dimmeler, S., Egido, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv236 · Cited by 200
Prins, B. P., Abbasi, A., Wong, A., Vaez, A., Nolte, I., Franceschini, N., Stuart, P. E., Guterriez Achury, J., Mistry, V., Bradfield, J. P., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001976 · Cited by 199
Short telomere length, myocardial infarction, ischemic heart disease, and early death
Weischer, M., Bojesen, S. E., Cawthon, R. M., Freiberg, J. J., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.237271 · Cited by 197
Self-citationThe link between benign prostatic hyperplasia and prostate cancer
Ørsted, D. D., & Bojesen, S. E. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2012.192 · Cited by 191
Mendelian randomization: use of genetics to enable causal inference in observational studies
Verduijn, M., Siegerink, B., Jager, K. J., Zoccali, C., & Dekker, F. W. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq098 · Cited by 189
Vitamin D concentration, obesity, and risk of diabetes: a mendelian randomisation study
Afzal, S., Brøndum-Jacobsen, P., Bojesen, S. E., & Nordestgaard, B. G. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70200-6 · Cited by 184
Self-citationNordestgaard, A. T., Thomsen, M., & Nordestgaard, B. G. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv083 · Cited by 189
Self-citationStender, S., Nordestgaard, B. G., & Tybjaerg-Hansen, A. (2013) · Hepatology · doi:10.1002/hep.26563 · Cited by 153
Self-citationClinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk
Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.082 · Cited by 174
Kessler, T., Vilne, B., & Schunkert, H. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506174 · Cited by 173
Neutrophil counts and cardiovascular disease
Luo, J., Thomassen, J. Q., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad649 · Cited by 167
“Particularly, for coronary artery disease, prior MR studies did not support C-reactive protein as a causal factor 20,21 but confirmed a potential causal role of the IL-6 receptor 22 in atherosclerotic cardiovascular disease.”
ResultSelf-citationTargeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
Aday, A. W., & Ridker, P. M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00016 · Cited by 173
Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study
Benn, M., Tybjærg-Hansen, A., Stender, S., Frikke-Schmidt, R., & Nordestgaard, B. G. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr008 · Cited by 167
Self-citationLow nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study
Thomsen, M., Varbo, A., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2013.219881 · Cited by 171
Self-citationVarbo, A., Benn, M., Smith, G. D., Timpson, N. J., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2015) · Circulation Research · doi:10.1161/circresaha.116.304846 · Cited by 171
Self-citationDoes Elevated C-Reactive Protein Increase Atrial Fibrillation Risk?
Marott, S. C. W., Nordestgaard, B. G., Zacho, J., Friberg, J., Jensen, G. B., Tybjærg-Hansen, A., & Benn, M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.066 · Cited by 162
Self-citationHemingway, H., Philipson, P., Chen, R., Fitzpatrick, N. K., Damant, J., Shipley, M., Abrams, K. R., Moreno, S., McAllister, K. S. L., Palmer, S., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000286 · Cited by 161
Pentraxins in innate immunity: lessons from PTX3
Deban, L., Jaillon, S., Garlanda, C., Bottazzi, B., & Mantovani, A. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1018-0 · Cited by 158
“Indeed, CRP gene polymorphisms associated with a marked increase in CRP levels are not in themselves associated with an increased risk of ischaemic vascular disease (Elliott et al. 2009; Zacho et al. 2008 ).”
BackgroundChange in Body Mass Index Associated With Lowest Mortality in Denmark, 1976-2013
Afzal, S., Tybjærg-Hansen, A., Jensen, G. B., & Nordestgaard, B. G. (2016) · JAMA · doi:10.1001/jama.2016.4666 · Cited by 152
Self-citationGenetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.045 · Cited by 156
Self-citationPlasma levels of apolipoprotein Eand risk of dementia in the general population
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology · doi:10.1002/ana.24326 · Cited by 156
Self-citationAngel, K., Provan, S. A., Gulseth, H. L., Mowinckel, P., Kvien, T. K., & Atar, D. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.143982 · Cited by 165
Periodontal therapy and cardiovascular risk
Orlandi, M., Graziani, F., & D'Aiuto, F. (2020) · Periodontology 2000 · doi:10.1111/prd.12299 · Cited by 155
Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality
Brouwers, M. C. G. J., Simons, N., Stehouwer, C. D. A., & Isaacs, A. (2020) · Diabetologia · doi:10.1007/s00125-019-05024-3 · Cited by 152
Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease
Kim, D. K., Cho, M. H., Hersh, C. P., Lomas, D. A., Miller, B. E., Kong, X., Bakke, P. S., Gulsvik, A., Agustí, A. G. N., Wouters, E. F. �., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1013oc · Cited by 158
Amezcua-Castillo, E., González‐Pacheco, H., Martín, A. S.-S., Méndez-Ocampo, P., Gutiérrez-Moctezuma, I., Massó, F., Sierra‐Lara, D., Springall, R., Rodríguez, E., Arias‐Mendoza, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092444 · Cited by 163
“A certain combination of CRP genotypes was associated with a significant 64% increase in CRP levels, although this elevation in CRP levels did not translate into a higher risk of ischemic vascular disease [34].”
Klovaite, J., Benn, M., Yazdanyar, S., & Nordestgaard, B. G. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04110.x · Cited by 150
Self-citationAllin, K. H., Nordestgaard, B. G., Flyger, H., & Bojesen, S. E. (2011) · Breast Cancer Research · doi:10.1186/bcr2891 · Cited by 144
Self-citationTayefi, M., Tajfard, M., Soflaei, S. S., Hanachi, P., Amirabadizadeh, A., Esmaily, H., Taghipour, A., Ferns, G. A., Moohebati, M., & Ghayour‐Mobarhan, M. (2017) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2017.02.001 · Cited by 152
Morris, P. G., Chen, C. C. L., Steingart, R. M., Fleisher, M., Lin, N., Moy, B., Come, S. E., Sugarman, S. M., Abbruzzi, A., Lehman, R. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1359 · Cited by 143
Metadata
- Authors
- Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Rigshospitalet (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-30
- Volume
- 359
- Issue
- 18
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081615427
- Cited by
- 839
- References
- 36
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 21 · 2023: 21 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 25 · 2018: 28 · 2017: 40 · 2016: 48 · 2015: 44 · 2014: 61 · 2013: 56 · 2012: 76
- FWCI
- 102.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- C-reactive protein, ischemic heart disease, ischemic cerebrovascular disease, ischemic vascular disease, CRP gene polymorphisms, apolipoprotein E, high-sensitivity CRP, genetic association, cholesterol levels, causal relationship
- MeSH terms
- C-Reactive Protein, Cerebrovascular Disorders, Cross-Sectional Studies, Female, Humans, Male, Polymorphism, Genetic, Risk Factors, Cohort Studies, Biomarkers, Myocardial Ischemia, Genetic Predisposition to Disease, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.